Rubrik: Aktuelle Epidemiologie und Diagnostik in der Mikrobiologie
Vibrio vulnificus – Infektiologischer Marker des Klimawandels? (S.26)
1. Farmer 3rd JJ. Vibrio ("Beneckea") vulnificus, the bacterium associated with sepsis, septicaemia, and the sea. Lancet 1979; 2(8148): 903. doi: 10.1016/s0140-6736(79)92715-6.
2. Baker-Austin C, Oliver JD. Vibrio vulnificus. Trends Microbiol 2020; 28(1): 81-82. doi: 10.1016/j.tim.2019.08.006.
3. Vu TTT, Alter T, Huehn S. Prevalence of Vibrio spp. in retail seafood in Berlin, Germany. J Food Prot 2018; 81(4): 593-597. doi: 10.4315/0362-028X.JFP-17-366.
4. Hartnell RE, Stockley L, Keay W, Rosec JP, Hervio-Heath D, Van den Berg H, Leoni F, Ottaviani D, Henigman U, Denayer S, Serbruyns B, Georgsson F, Krumova-Valcheva G, Gyurova E, Blanco C, Copin S, Strauch E, Wieczorek K, Lopatek M, Britova A, Hardouin G, Lombard B, In't Veld P, Leclercq A, Baker-Austin C. A pan-European ring trial to validate an international standard for detection of Vibrio cholerae, Vibrio parahaemolyticus and Vibrio vulnificus in seafoods. Int J Food Microbiol 2019; 288: 58-65. doi: 10.1016/j.ijfoodmicro.2018.02.008.
5. International Organization for Standardization (ISO). https://www.iso.org/standard/74112.html
6. Böer SI, Heinemeyer EA, Luden K, Erler R, Gerdts G, Janssen F, Brennholt N. Temporal and spatial distribution patterns of potentially pathogenic Vibrio spp. at recreational beaches of the German North Sea. Microb Ecol 2013; 65(4): 1052-1067. doi: 10.1007/s00248-013-0221-4.
7. Fleischmann S, Herrig I, Wesp J, Stiedl J, Reifferscheid G, Strauch E, Alter T, Brennholt N. Prevalence and distribution of potentially human pathogenic Vibrio spp. on German North and Baltic Sea coasts. Front Cell Infect Microbiol 2022; 12: 846819. doi: 10.3389/fcimb.2022.846819.
8. Huehn S, Eichhorn C, Urmersbach S, Breidenbach J, Bechlars S, Bier N, Alter T, Bartelt E, Frank C, Oberheitmann B, Gunzer F, Brennholt N, Böer S, Appel B, Dieckmann R, Strauch E. Pathogenic vibrios in environmental, seafood and clinical sources in Germany. Int J Med Microbiol 2014; 304(7): 843-850. doi: 10.1016/j.ijmm.2014.07.010.
9. Kuhnt-Lenz K, Krengel S, Fetscher S, Heer-Sonderhoff A, Solbach W. Sepsis with bullous necrotizing skin lesions due to vibrio vulnificus acquired through recreational activities in the Baltic Sea. Eur J Clin Microbiol Infect Dis 2004; 23(1): 49-52. doi: 10.1007/s10096-003-1056-6.
10. Frank C, Littman M, Alpers K, Hallauer J. Vibrio vulnificus wound infections after contact with the Baltic Sea, Germany. Euro Surveill 2006; 11(8): E060817.1. doi: 10.2807/esw.11.33.03024-en.
11. Brehm TT, Berneking L, Sena Martins M, Dupke S, Jacob D, Drechsel O, Bohnert J, Becker K, Kramer A, Christner M, Aepfelbacher M, Schmiedel S, Rohde H; German Vibrio Study Group. Heatwave-associated Vibrio infections in Germany, 2018 and 2019. Euro Surveill 2021; 26(41): 2002041. doi: 10.2807/1560-7917.ES.2021.26.41.2002041.
12. Meyer HL, Polan C, Burggraf M, Podleska L, Beck P, Steinau HU, Dudda M, Farzaliyev F. "The Baltic Sea Germ": A case report of necrotizing fasciitis following Vibrio vulnificus infection. Case Rep Orthop 2022; 2022: 5908666. doi: 10.1155/2022/5908666.
13. Bier N, Jäckel C, Dieckmann R, Brennholt N, Böer SI, Strauch E. Virulence profiles of Vibrio vulnificus in German coastal waters, a comparison of North Sea and Baltic Sea isolates. Int J Environ Res Public Health 2015; 12(12): 15943-15959. doi: 10.3390/ijerph121215031.
14. Dupke S, Buchholz U, Fastner J, Förster C, Frank C, Lewin A, Rickerts V, Selinka HC. Impact of climate change on waterborne infections and intoxications. J Health Monit 2023; 8(Suppl 3): 62-77. doi: 10.25646/11402.
15. Meier HEM, Dieterich C, Eilola K, Gröger M, Höglund A, Radtke H, Saraiva S, Wåhlström I. Future projections of record-breaking sea surface temperature and cyanobacteria bloom events in the Baltic Sea. Ambio 2019; 48(11): 1362-1376. doi: 10.1007/s13280-019-01235-5.
16. Schütt EM, Hundsdörfer MAJ, von Hoyningen-Huene AJE, Lange X, Koschmider A, Oppelt N. First steps towards a near real-time modelling system of Vibrio vulnificus in the Baltic Sea. Int J Environ Res Public Health 2023; 20(8): 5543. doi: 10.3390/ijerph20085543.
17. Paz S, Bisharat N, Paz E, Kidar O, Cohen D. Climate change and the emergence of Vibrio vulnificus disease in Israel. Environ Res 2007; 103(3): 390-396. doi: 10.1016/j.envres.2006.07.002.
18. Urquhart EA, Zaitchik BF, Waugh DW, Guikema SD, Del Castillo CE. Uncertainty in model predictions of Vibrio vulnificus response to climate variability and change: a Chesapeake Bay case study. PLoS One 2014; 9(5): e98256. doi: 10.1371/journal.pone.0098256.
19. Baker-Austin C, Trinanes J, Gonzalez-Escalona N, Martinez-Urtaza J. Non-Cholera Vibrios: the microbial barometer of climate change. Trends Microbiol 2017; 25(1): 76-84. doi: 10.1016/j.tim.2016.09.008.
20. Deeb R, Tufford D, Scott GI, Moore JG, Dow K. Impact of climate change on Vibrio vulnificus abundance and exposure risk. Estuaries Coast 2018; 41(8): 2289-2303. doi: 10.1007/s12237-018-0424-5.
21. Froelich BA, Daines DA. In hot water: effects of climate change on Vibrio-human interactions. Environ Microbiol 2020; 22(10): 4101-4111. doi: 10.1111/1462-2920.14967.
22. Archer EJ, Baker-Austin C, Osborn TJ, Jones NR, Martínez-Urtaza J, Trinanes J, Oliver JD, González FJC, Lake IR. Climate warming and increasing Vibrio vulnificus infections in North America. Sci Rep 2023; 13(1): 3893. doi: 10.1038/s41598-023-28247-2.
23. Brumfield KD, Chen AJ, Gangwar M, Usmani M, Hasan NA, Jutla AS, Huq A, Colwell RR. Environmental factors influencing occurrence of Vibrio parahaemolyticus and Vibrio vulnificus. Appl Environ Microbiol 2023; 89(6): e0030723. doi: 10.1128/aem.00307-23.
24. Almagro-Moreno S, Martinez-Urtaza J, Pukatzki S. Vibrio infections and the twenty-first century. Adv Exp Med Biol 2023; 1404: 1-16. doi: 10.1007/978-3-031-22997-8_1.
25. European Centre for Disease Prevention and Control (ECDC). https://geoportal.ecdc.europa.eu/vibriomapviewer/
26. Sunderkötter C, Becker K, Eckmann C, Graninger W, Kujath P, Schöfer H. S2k-Leitlinie Haut- und Weichgewebeinfektionen (Auszug aus: Paul-Ehrlich-Gesellschaft für Chemotherapie e.v.; Kalkulierte parenterale Initialtherapie bakterieller Erkrankungen bei Erwachsenen - Update 2018). J Dtsch Dermatol Ges 2019; 17(3): 345-371. doi: 10.1111/ddg.13790_g.
27. Robert Koch-Institut (RKI). https://www.rki.de/DE/Content/Infekt/NRZ/Konsiliar/Vibrionen/vibrionen_node.html
Das Auf und Ab der Clostridioides-difficile-Infektion (S.26)
1. Di Bella S, Sanson G, Monticelli J, Zerbato V, Principe L, Giuffrè M, Pipitone G, Luzzati R. Clostridioides difficile infection: history, epidemiology, risk factors, prevention, clinical manifestations, treatment, and future options. Clin Microbiol Rev. 2024 Feb 29:e0013523. doi: 10.1128/cmr.00135-23.
2. Weinke T, Beier D, Brestrich G, von Eiff C, Häckl D, Heinrich K, Moïsi J, Schley K. Epidemiology and risk factors of Clostridioides difficile infections in Germany: A health claims data analysis. Infect Dis Ther 2023; 12: 1299-1317. doi: 10.1007/s40121-023-00800-6.
3. Brestrich G, Angulo FJ, Berger FK, Brösamle C, Hagel S, Leischker A, Lübbert C, Maechler F, Merbecks SS, Minarovic N, Moïsi JC, von Müller L, Reuken PA, Weinke T, Yu H, Mellmann A. Epidemiology of Clostridioides difficile infections in Germany, 2010-2019: A review from four public databases. Infect Dis Ther 2023; 12: 1057-1072. doi: 10.1007/s40121-023-00785-2.
4. Warny M, Pepin J, Fang A, Killgore G, Thompson A, Brazier J, Frost E, McDonald LC. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 2005; 366: 1079-1084. doi: 10.1016/S0140-6736(05)67420-X.
5. McDonald LC, Owings M, Jernigan DB. Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996-2003. Emerg Infect Dis 2006; 12: 409-415. doi: 10.3201/eid1205.051064.
6. Vonberg RP, Schwab F, Gastmeier P. Clostridium difficile in discharged inpatients, Germany. Emerg Infect Dis 2007; 13: 179-80. doi: 10.3201/eid1301.060611.
7. Abdrabou AMM, Ul Habib Bajwa Z, Halfmann A, Mellmann A, Nimmesgern A, Margardt L, Bischoff M, von Müller L, Gärtner B, Berger FK. Molecular epidemiology and antimicrobial resistance of Clostridioides difficile in Germany, 2014-2019. Int J Med Microbiol 2021; 311: 151507. doi: 10.1016/j.ijmm.2021.151507.
8. Abdrabou AMM, Sy I, Bischoff M, Arroyo MJ, Becker SL, Mellmann A, von Müller L, Gärtner B, Berger FK. Discrimination between hypervirulent and non-hypervirulent ribotypes of Clostridioides difficile by MALDI-TOF mass spectrometry and machine learning. Eur J Clin Microbiol Infect Dis 2023; 42: 1373-1381. doi: 10.1007/s10096-023-04665-y.
9. Couturier J, Davies K, Barbut F. Ribotypes and new virulent strains across Europe. Adv Exp Med Biol 2024; 1435: 151-168. doi: 10.1007/978-3-031-42108-2_8.
10. Verordnung zur Annpassung der Meldepflichten nach dem Infektionsschutzgesetz an die epidemische Lage (IfSG-Meldepflicht-Anpassungsverordnung – IfSGMeldAnpV) vom 18. März 2016. Bundesgesestzblatt 2016, Teil I Nr 13 vom 31. März 2016, 515. https://www.bgbl.de/xaver/bgbl/start.xav?startbk=Bundesanzeiger_BGBl&start=//*%255B@attr_id=%27bgbl116s0515.pdf%27%255D
11. Statistisches Bundesamt. https://www.destatis.de/DE/Themen/Querschnitt/Demografischer-Wandel/demografie-mitten-im-wandel.html
12. Robert Koch-Institut (RKI). https://survstat.rki.de
13. Heudorf U, Berres M, Dogan O, Steul KS. Meldepflicht für schwere Clostridiodes difficile- Infektionen – Daten aus Frankfurt am Main, 2014–2018. Bestandsaufnahme und Diskussion. Gesundheitswesen 2022; 84: 293-300. doi: 10.1055/a-1330-8293.
14. Nationales Referenzzentrum (NRZ) für die Surveillance von nosokomialen Infektionen. Referenzdaten des Moduls CDI-KISS (Stand: Mai 2023). https://www.nrz-hygiene.de/files/Referenzdaten/CDAD/202201_202212_CDI_Ref.pdf
15. Kommission für Krankenhaushygiene und Infektionsprävention (KRINKO) beim Robert Koch-Institut (RKI). Hygienemaßnahmen bei Clostridioides difficile-Infektion (CDI). Bundesgesundheitsbl 2019; 62: 906–923. doi: 10.1007/s00103- 019- 02959-1.
16. Schönherr S, Jung L, Lübbert C. Clostridioides difficile – Neue Erkenntnisse und Therapieempfehlungen. Dtsch Med Wochenschr 2023; 148: 752-758. doi: 10.1055/a-1970-9211.
17. van Prehn J, Reigadas E, Vogelzang EH, Bouza E, Hristea A, Guery B, Krutova M, Norén T, Allerberger F, Coia JE, Goorhuis A, van Rossen TM, Ooijevaar RE, Burns K, Scharvik Olesen BR, Tschudin-Sutter S, Wilcox MH, Vehreschild MJGT, Fitzpatrick F, Kuijper EJ; Guideline Committee of the European Study Group on Clostridioides difficile. European Society of Clinical Microbiology and Infectious Diseases: 2021 update on the treatment guidance document for Clostridioides difficile infection in adults. Clin Microbiol Infect 2021; 27 Suppl 2: S1-S21. doi: 10.1016/j.cmi.2021.09.038.
18. Vehreschild MJGT, Schreiber S, von Müller L, Epple HJ, Weinke T, Manthey C, Oh J, Wahler S, Stallmach A. Trends in the epidemiology of Clostridioides difficile infection in Germany. Infection 2023; 51: 1695-1702. doi: 10.1007/s15010-023-02044-5.
19. Wendt S, Ranft D, de With K, Kern WV, Salzberger B, Lübbert C. Antibiotic Stewardship (ABS). Teil 2: Anwendung. Internist (Berl). 2020; 61: 475-486. doi: 10.1007/s00108-020-00763-7.
20. Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF) e. V. Strategien zur Sicherung rationaler Antibiotika-Anwendung im Krankenhaus. S3-Leitlinie (Stand: Januar 2019). Registernummer 092-001. https://register.awmf.org/assets/guidelines/092-001l_S3_Strategien-zur-Sicherung-rationaler-Antibiotika-Anwendung-im-Krankenhaus_2020-02-abgelaufen.pdf
21. Baur D, Gladstone BP, Burkert F, Carrara E, Foschi F, Döbele S, Tacconelli E. Effect of antibiotic stewardship on the incidence of infection and colonisation with antibiotic-resistant bacteria and Clostridium difficile infection: a systematic review and meta-analysis. Lancet Infect Dis 2017; 17: 990-1001. doi: 10.1016/S1473-3099(17)30325-0.
Rubrik: Neue Substanzen
Rezafungin – ein neues Echinocandin-Antimykotikum (S. 27)
1. European Medicines Agency (EMA). Assessment report Rezzayo (Rezafungin). published online Oct 12, 2023. https://www.ema.europa.eu/en/documents/assessment-report/rezzayo-epar-public-assessment-report_en.pdf [10.04.2024]
2. Robert Koch Institut (RKI). Mykosen (Pilzinfektionen) - Candidiasis; Stand 13.06.2023.
https://www.rki.de/DE/Content/InfAZ/P/Pilzinfektionen/Candida_spp.html [10.04.2024]
3. Groll, A.H. et al. S1 Leitlinie Diagnose und Therapie von Candida Infektionen: Gemeinsame Empfehlungen der Deutschsprachigen Mykologischen Gesellschaft (DMykG) und der Paul-Ehrlich-Gesellschaft für Chemotherapie (PEG) ICD 10: B37.-. Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften eV, 2020. https://register.awmf.org/assets/guidelines/082-005l_S1_Diagnose-Therapie-Candida-Infektionen_2020-09.pdf
4. Garcia-Effron G. Rezafungin—Mechanisms of Action, Susceptibility and Resistance: Similarities and Differences with the Other Echinocandins. J Fungi 2020;6(4):262. doi: 10.3390/jof6040262
5. Fachinformation Rezzayo (Rezafungin), Mundipharma, Stand 12/2023.
https://mundi-pharma-ger-d9.pid2-e1.investis.com/sites/mundi-pharma-ger/files/mundipharma-ger/products/RezzayoFachinformation.pdf
6. Arendrup MC et al. Multicentre validation of a modified EUCAST MIC testing method and development of associated epidemiologic cut-off (ECOFF) values for rezafungin. J Antimicrob Chemother. 2022;78(1):185-95. doi: 10.1093/jac/dkac373.
7. Hoenigl M et al. The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin. Drugs. 2021;81(15):1703-29. doi:10.1007/s40265-021-01611-0
8. Thompson GR et al. Rezafungin Versus Caspofungin in a Phase 2, Randomized, Double-blind Study for the Treatment of Candidemia and Invasive Candidiasis: The STRIVE Trial. Clinical Infectious Diseases. 2020;73(11):e3647-e55. doi: 10.1093/cid/ciaa1380
9. Thompson GR et al. Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase 3 trial. Lancet. 2023;401(10370):49-59. doi: 10.1016/s0140-6736(22)02324-8
Aztreonam/Avibactam – eine neue Antibiotika-Kombination aus alten Bekannten (S. 30)
1. World Health Organization (WHO). WHO Bacterial Priority Pathogens List, 2024: bacterial pathogens of public health importance to guide research, development and strategies to prevent and control antimicrobial resistance. published online May 17, 2024. https://iris.who.int/bitstream/handle/10665/376776/9789240093461-eng.pdf?sequence=1 [01.06.2024]
2. European Medicines Agency (EMA). Assessment report Emblaveo (Aztreonam/Avibactam). Stand: 21.03.2024. https://www.ema.europa.eu/en/documents/assessment-report/emblaveo-epar-public-assessment-report_en.pdf [01.06.2024]
3. European Medicines Agency (EMA). Zusammenfassung der Merkmale des Arzneimittels Emblaveo (Aztreonam/Avibactam). published online May 07, 2024. https://www.ema.europa.eu/de/documents/product-information/emblaveo-epar-product-information_de.pdf [02.06.2024]
4. Nordmann P et al. Recent Emergence of Aztreonam-Avibactam Resistance in NDM and OXA-48 Carbapenemase-Producing Escherichia coli in Germany. Antimicrob Agents Chemother 2021; 65(11): e0109021. doi: 10.1128/aac.01090-21
5. Mauri C et al. The Revival of Aztreonam in Combination with Avibactam against Metallo-β-Lactamase-Producing Gram-Negatives: A Systematic Review of In Vitro Studies and Clinical Cases. Antibiotics (Basel) 2021; 10(8):1012. doi: 10.3390/antibiotics10081012
6. Tamma PD et al. Infectious Diseases Society of America 2023 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections. Clin Infect Dis 2023; published online first Jul 18, 2023. doi: 10.1093/cid/ciad428.
